retatrutide fat loss results Phase III study demonstrates 30% weight 28.7% Weight Loss in New

These findings robustly support the notion that TLR2 pep-orid-liposome facilitates delivery of the drug specifically to tumor sites, thus minimizing off-target effects in the liver while maximizing therapeutic efficacy against AML cancer cells

IGF-1 LR3 + Ipamorelin Combines direct IGF-1 receptor activation with pulsatile GH release

Youre eating less

Blocks melanin production for gradual, natural lightening

Novo Nordisk maintains first-to-market advantage with semaglutide across diabetes (Ozempic), obesity (Wegovy), and oral (Rybelsus) formulations, with the oral version launching in January 2026 following December 2025 FDA approval [3]